Group 1 - Vigil Neuroscience, Inc. (VIGL) has recently experienced a "golden cross" event, indicating a potential bullish breakout from a technical perspective [1][2] - A golden cross occurs when a stock's short-term moving average, typically the 50-day, crosses above its long-term moving average, such as the 200-day, suggesting stronger breakouts [2] - VIGL has rallied 186.9% over the past four weeks, and it currently holds a 2 (Buy) rating on the Zacks Rank, indicating a strong potential for further gains [4] Group 2 - The bullish outlook for VIGL is supported by a positive earnings forecast, with five upward revisions in earnings estimates over the past 60 days and no downward revisions [4][6] - The combination of the positive technical indicators and the favorable earnings outlook suggests that investors should monitor VIGL for potential gains in the near future [6]

Group 1 - Class Action Attorney Juan Monteverde's firm, Monteverde & Associates PC, is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has recovered millions for shareholders [1] - Vigil Neuroscience, Inc. (NASDAQ: VIGL) is under investigation regarding its proposed merger with Sanofi, which includes an upfront payment of $8.00 per share in cash [1] - The total equity value of the transaction, including a potential contingent value right (CVR) payment of $2.00 per share, is approximately $600 million on a fully diluted basis [1]

Shares of Vigil Neuroscience, Inc. (VIGL) have gained 340.2% over the past four weeks to close the last trading session at $7.88, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.71 indicates a potential upside of 86.7%.The mean estimate comprises seven short-term price targets with a standard deviation of $4.75. While the lowest estimate of $8 indicates a 1.5% increase from ...

Core Viewpoint - Sanofi has entered into a definitive merger agreement to acquire Vigil Neuroscience for an upfront payment of $8.00 per share, with potential additional payments based on the commercial success of VG-3927, valuing the total equity of the transaction at approximately $600 million on a fully diluted basis [1][5][6]. Company Overview - Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases by restoring the function of microglia, the immune cells of the brain [11]. - The company is developing VG-3927, a small molecule TREM2 agonist aimed at treating Alzheimer's disease, and has a pipeline that includes therapies for both rare and common neurodegenerative diseases [11]. Transaction Details - The merger agreement stipulates that Vigil's shareholders will receive $8.00 per share in cash at closing, plus a contingent value right (CVR) that could yield an additional $2.00 per share upon the first commercial sale of VG-3927 [1][5][6]. - The acquisition is expected to close in the third quarter of 2025, subject to customary conditions including shareholder approval and regulatory clearances [8]. Strategic Rationale - Sanofi's acquisition of Vigil aligns with its strategic focus on neurology and the development of innovative therapies for critical unmet needs in neurodegenerative diseases [4]. - The TREM2 target is seen as a promising area for addressing immune dysregulation and neurodegeneration, particularly in Alzheimer's patients who currently have limited treatment options [4][2]. Development Potential - The acquisition is anticipated to strengthen the development path for VG-3927, which is positioned as a Phase 2-ready clinical candidate for Alzheimer's disease [5][6]. - Activating TREM2 is expected to enhance the neuroprotective function of microglia, potentially preventing neural degeneration associated with adult-onset neurodegenerative diseases [2][3].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number 001-41200 VIGIL NEUROSCIENCE, INC. (Exact name of Registrant as specified in its Charter) De ...

Exhibit 99.1 Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates – On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – - Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer's disease in Q3 2025 – WATERTOWN, Mass., May. 7, 2025 — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neur ...

"During the quarter, we continued to make meaningful progress across our two TREM2 programs, VG-3927 and iluzanebart," said Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. "For VG-3927, we reported positive Phase 1 data in January 2025 that support the planned initiation of a Phase 2 trial in Alzheimer's disease patients in Q3. We also presented these findings at the AD/PD™ scientific conference, further highlighting VG-3927's potential as a differentiated next-genera ...

- Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG-3927 - - First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment of Alzheimer’s disease (AD) - WATERTOWN, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented data highlighting ...

Vigil Neuroscience, Inc. (VIGL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power o ...

Financial Performance - The company incurred a net loss of $84.3 million for the year ended December 31, 2024, with an accumulated deficit of $307.0 million as of the same date[215]. - The company expects to continue incurring significant losses for the foreseeable future, with anticipated increases in losses as development and commercialization efforts continue[215]. - The company believes its existing cash, cash equivalents, and marketable securities will fund operations into 2026, but there is substantial doubt about its ability to continue as a going concern[220]. - The company has not generated any product revenue since its inception and does not have any products approved for sale[215]. - The company currently generates no revenue from product sales and may never be able to commercialize a marketable product[241]. Development and Regulatory Challenges - The company has not yet completed any late-stage clinical trials or obtained regulatory approvals for its therapeutic candidates[214]. - The company faces significant risks and uncertainties associated with biopharmaceutical product development, making future success difficult to predict[216]. - The company’s operating results may fluctuate significantly due to various factors, including regulatory approvals and market acceptance of its therapeutic candidates[226]. - The company may face significant delays or inability to successfully commercialize therapeutic candidates if it does not meet regulatory requirements or complete necessary studies[244]. - The company is highly dependent on the success of ongoing and future clinical trials of its lead clinical candidate, iluzanebart, and any issues could significantly harm its business[245]. Financing and Capital Requirements - The company will require additional financing to achieve its goals, and failure to obtain necessary capital could delay or terminate development programs[220]. - The company has sold 8,671,793 shares of common stock under its ATM program, generating aggregate net proceeds of $22.8 million as of March 11, 2025, with approximately $76.5 million remaining available for issuance[235]. - The company has filed a Registration Statement for the registration of common stock, preferred stock, debt securities, warrants, and units, with an aggregate amount of $100.0 million under the 2023 Shelf[235]. - The company may need to turn to other funding sources if it cannot raise additional equity capital through its ATM program, which could adversely affect its operations[236]. Clinical Trials and Product Development - The lead clinical candidate, iluzanebart, is currently being studied in a Phase 2 clinical trial for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP)[239]. - VG-3927, a novel small molecule TREM2 agonist, is being developed for the treatment of common neurodegenerative diseases, with completed data from a Phase 1 clinical trial for Alzheimer's disease reported in January 2025[240]. - Clinical trials are expensive and can take many years to complete, with outcomes being inherently uncertain, potentially leading to delays in regulatory approvals[254]. - The company may encounter substantial delays in clinical trial enrollment and completion due to challenges in identifying eligible patients, particularly for rare diseases[258]. - The company’s product development costs will increase if there are delays in clinical testing or marketing approvals, potentially impairing its ability to commercialize therapeutic candidates[264]. Intellectual Property Risks - The company faces risks related to intellectual property disputes that could impair its ability to commercialize therapeutic candidates[300]. - The company relies on third-party licensors for important patent and intellectual property rights, which could impact the development of therapeutic programs[327]. - The patent prosecution process is expensive and complex, and the company may not be able to maintain or enforce all necessary patents[322]. - The company may face challenges in protecting its intellectual property rights globally, leading to potential vulnerabilities in certain jurisdictions[334]. - The validity and enforceability of the company's patents covering therapeutic candidates may be challenged, leading to potential narrowing or invalidation of patent rights, which could materially impact its business[337]. Regulatory Compliance and Legal Risks - The company must comply with regulatory requirements for clinical trials, and failure to do so could result in significant delays and penalties[304]. - The company is subject to the EU General Data Protection Regulation (GDPR), which imposes strict requirements on the handling of personal data and could result in substantial fines for non-compliance[368]. - The company faces intense competition for qualified personnel in the Boston area, which may hinder its ability to attract and retain skilled employees necessary for growth[411]. - Compliance with evolving privacy and data security laws could increase costs and expose the company to significant fines or penalties[363]. - The company may face claims challenging the inventorship or ownership of its intellectual property rights, which could result in litigation and loss of valuable rights if unsuccessful[346]. Market and Competitive Landscape - The commercial success of therapeutic candidates depends on market acceptance by physicians, patients, and healthcare payors, which is influenced by factors such as clinical efficacy, pricing, and reimbursement availability[394][396]. - Future healthcare reforms may result in more rigorous coverage criteria and downward pressure on product pricing, impacting revenue generation and profitability[401]. - The ability to commercialize therapeutic candidates is contingent on adequate coverage and reimbursement from government and private payors, which is critical for new product acceptance[399][400]. - The company faces significant liabilities from clinical trial and product liability lawsuits, which could divert resources and limit commercialization efforts[281]. Employee and Management Risks - The company faces challenges in retaining key personnel, which could adversely affect business and product development[412]. - The employment of key employees is at-will, allowing them to leave with or without notice[412]. - The company has implemented stock options that vest over time to retain valuable employees, which may be affected by stock price movements[412]. - In May 2024, the board of directors approved a stock option repricing to provide added incentives for key contributors[412].